This distinction is important because CBD does not have the intoxicating feeling associated with THC. Instead, it has been shown t o have anti-anxiety properties that can help manage behavior and promote calm. Additionally, CBD is the main ingredient in recent FDA-approved medication, Epidiolex, to treat epilepsy.
What Are the Benefits of CBD for Seniors with Dementia?
Because of how dementia affects the brain, a senior may become agitated or anxious in everyday situations. Sometimes this agitation can even turn vio lent. But remember that these behavior changes are caused by the disease and are not your loved one’s fault. CBD may be able to help alleviate these symptoms .
Let’s dive deeper into how CBD could help in each of these areas.
While this information gives us much hope in the fight against dementia, know that only small clinical trials have been conducted to determine the effects of CBD on dementia, making it difficult to come to a scientific conclusion. However, scientists are continuing to conduct rese arch to help further our ability to help those with dementia.
Studies have reported changes in the endocannabinoid system in the brain of patients with Alzheimer’s disease (AD), playing a role in the pathophysiology of AD. Cannabinoids have been shown to have neuroprotective properties, reduce neuroinflammation, and enhance neurogenesis. Evidence suggests that the utilization of marijuana products containing both tetrahydrocannabinol (THC) and cannabidiol (CBD) or CBD alone have been effective and safe for use in older people with agitation associated with dementia. A review in 2017 summarized positive findings for therapeutic benefits of cannabinoids in agitation of AD and dementia, but there was no definitive conclusion because of varying cannabinoid products. Cannabinoids were shown to be well tolerated, with few short-term side effects. This differs from first-line medications utilized for dementia behaviors, which can have unwanted side effects. Further research regarding the safety, efficacy, and variability of these products in older people is needed.
Individuals with Alzheimer’s and other forms of dementia often go through a period of significant behavioral and psychological symptoms of dementia (BPSD). It is estimated that up to 90% of persons with dementia (PWD) experience behavior problems at some point. BPSDs can be challenging for both unpaid family caregivers as well as paid caregivers. Family caregivers provide the bulk of care for PWD and number over 15 million. One of the most common types of BPSDs is agitation with a prevalence of up to 87%, based on a recent systematic review. Agitation can lead to impaired daily functioning, prolongation of hospitalization, reduced time to institutionalization, and is associated with higher mortality. Additionally, agitated behavior is associated with increased injury to both patients and caregivers. Based on the 2018 Alzheimer’s disease drug development pipeline report almost 70% of clinical trials related to BPSD are dedicated to agitation behavior. Finding ways to address agitation is necessary to improve overall quality of life for PWD and their caregivers. Currently, there are no medications available specifically for the treatment of BPSDs. The use of benzodiazepines, antipsychotics and mood stabilizing agents are common, but the risks and side effects often outweigh any benefits.